ONO 2506

Key Product Details

Product Description

ONO 2506 inhibits S-100β synthesis in activated cultured astrocytes. Prevents delayed infarct expansion 24 hours after permanent middle cerebral artery occlusion (pMCAO) in rats; also exhibits neuroprotective effects in mouse models of Parkinson's disease and Alzheimer's disease.

Product Specifications for ONO 2506

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for ONO 2506

The following data is based on the product molecular weight 186.29.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

2 1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	5.37 mL	26.84 mL	53.68 mL
5 mM	1.07 mL	5.37 mL	10.74 mL
10 mM	0.54 mL	2.68 mL	5.37 mL
50 mM	0.11 mL	0.54 mL	1.07 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 4 publications citing the usage of this product.

• Tateishi Astrocytic activation and delayed infarct expansion after permanent focal ischemia in rats. Part II: suppression of astrocytic activation by a novel agent (R)-(-)-2-propyloctanoic acid (ONO-2506) leads to mitigation of delayed infarct expansion and early J.Cereb.Blood Flow Metab. 2002 PMID: 12045671
• Mori Arundic acid ameliorates cerebral amyloidosis and gliosis in Alzheimer transgenic mice. J.Pharmacol.Exp.Ther. 2006 PMID: 16709678
• Kato Arundic acid, an astrocyte-modulating agent, protects DArgic neurons against MPTP neurotoxicity in mice. Brain Res. 2004 PMID: 15567338

Product Documents for ONO 2506